JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

Sponsor
West China Hospital
Study ID
NCT07175389
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Refractory Pancreatic Adenocarcinoma
  • Refractory Pancreatic Ductal Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • JDB153 — DRUG
    JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.
  • Serplulimab — DRUG
    Serplulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).

Study Details

The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.

Key Dates

Start date
Oct 1, 2025
Status verified
Sep 2025
Primary completion
Sep 1, 2027
Completion
Oct 1, 2027

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: JDB153 combined with Serplulimab

Primary Outcome Measure

Incidence of Treatment-Related Adverse Events [ Time Frame: Approximately 2 years ]

Central Contacts

Related Studies